Eris Lifesciences Ltd, founded in 2007 and headquartered in Ahmedabad, Gujarat, is a prominent player in the Indian pharmaceutical industry, known for its focus on the domestic branded formulations market. The company has carved a niche for itself in the chronic and sub-chronic therapeutic areas, with a strong foothold in the cardio-metabolic segment. Beyond this, Eris is expanding its portfolio into other therapeutic domains such as dermatology, neuropsychiatry, women’s health, and nephrology, demonstrating a broadening scope of expertise. Operating with a pure-play business model, Eris Lifesciences targets only the Indian market, ensuring a deep understanding of local healthcare needs and market dynamics.
The company’s manufacturing facilities in Guwahati and Gujarat underpin its integrated approach, supporting its strategic expansion and supply chain efficiency. Eris is also committed to advancing research and development through various India-centric studies, including the India Heart Study and the India Diabetes Study, which aim to enhance disease management and treatment outcomes for Indian patients. With a mission to make a meaningful impact in managing chronic lifestyle-related diseases, Eris Lifesciences is dedicated to delivering innovative therapies and patient care initiatives, reinforcing its role as a key player in the Indian pharmaceutical landscape.
Latest News on ERIS Lifesciences Ltd
Recently, Eris Lifesciences Ltd made a strategic move by acquiring Biocon Biologics’ India-branded formulations business for ₹1,242 crore, marking its entry into the injectables market and strengthening its position in the insulin segment, which aligns with its focus on managing chronic diseases like diabetes. This acquisition is expected to expand Eris’s product portfolio and enhance its presence in the rapidly growing Indian pharmaceutical market. Additionally, ChrysCapital, a private equity firm, exited Eris by selling its entire 7.27% stake for ₹1,187 crore, signaling a major private equity withdrawal in the sector and showcasing investor confidence in Eris’s growth potential and market valuation. These developments underscore Eris’s dynamic strategy to diversify its offerings and maintain its competitive edge in the industry.
Shareholding Patterns of ERIS Lifesciences
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | |
| Promoters + | 52.86% | 54.91% | 54.90% | 54.90% | 54.88% |
| FIIs + | 13.78% | 13.20% | 13.13% | 14.27% | 14.59% |
| DIIs + | 10.73% | 14.52% | 14.55% | 15.63% | 16.23% |
| Public + | 22.63% | 17.37% | 17.41% | 15.20% | 14.30% |
| No. of Shareholders | 44,169 | 42,245 | 46,496 | 51,753 | 44,176 |
The shareholding pattern of Eris Lifesciences Ltd has experienced notable changes over the period from June 2023 to June 2024. The promoters consistently maintained a majority stake, with their shareholding fluctuating slightly from 52.86% in June 2023 to 54.88% in June 2024, showing a gradual increase in the first half and a stable holding thereafter. Foreign Institutional Investors (FIIs) showed a minor decrease initially, moving from 13.78% in June 2023 to 13.13% in December 2023, but their stake rose significantly to 14.59% by June 2024, indicating renewed interest. Domestic Institutional Investors (DIIs) steadily increased their shareholding from 10.73% in June 2023 to 16.23% in June 2024, reflecting strong confidence in the company’s prospects. Meanwhile, the public shareholding saw a decline from 22.63% in June 2023 to 14.30% in June 2024, suggesting a consolidation of shares among larger investors. The number of shareholders also fluctuated, peaking at 51,753 in March 2024 before settling at 44,176 in June 2024, indicating a dynamic shareholder base over the year.
How to Buy Eris Lifesciences Ltd Shares in India?
You can buy Eris Lifesciences Ltd shares in India by opening a trading account with a broker. You will need to provide your personal details, such as your PAN number, bank details, and other personal documents. Once the trading account is opened, you can buy Berger Paints shares using the broker’s online trading platform. You can also buy Eris Lifesciences Ltd shares through a mutual fund or a portfolio management service. Some online platforms to buy shares are Zerodha, Sharekhan, and Upstox.
Eris Lifesciences Share Price Target: 2024 to 2030
Eris Lifesciences Share Price Target 2024
| When | Maximum Price | Minimum Price |
| September 2024 | 1,474.15 | 1,281.87 |
| October 2024 | 1,459.56 | 1,269.18 |
| November 2024 | 1,517.94 | 1,319.95 |
| December 2024 | 1,533.12 | 1,333.15 |
In September 2024, Eris Lifesciences is projected to reach a maximum price of ₹1,474.15 and a minimum price of ₹1,281.87. Moving into October, the stock is expected to see a maximum of ₹1,459.56 and a minimum of ₹1,269.18. In November, Eris Lifesciences’ stock may climb to a maximum of ₹1,517.94, with the minimum anticipated at ₹1,319.95. By December 2024, the maximum price is forecasted to be ₹1,533.12, while the minimum could settle around ₹1,333.15.
Eris Lifesciences Share Price Target 2025
| When | Maximum Price | Minimum Price |
| January 2025 | 1,548.45 | 1,191.12 |
| February 2025 | 1,564.09 | 1,203.15 |
| March 2025 | 1,596.94 | 1,228.41 |
| April 2025 | 1,581.13 | 1,216.25 |
| May 2025 | 1,535.07 | 1,180.83 |
| June 2025 | 1,604.15 | 1,233.96 |
| July 2025 | 1,572.70 | 1,209.77 |
| August 2025 | 1,621.34 | 1,247.18 |
| September 2025 | 1,640.80 | 1,262.15 |
| October 2025 | 1,683.46 | 1,294.97 |
| November 2025 | 1,725.54 | 1,327.34 |
| December 2025 | 1,803.19 | 1,387.07 |
As we step into January 2025, Eris Lifesciences is expected to see a maximum price of ₹1,548.45 and a minimum of ₹1,191.12. By December 2025, the stock may reach a maximum of ₹1,803.19 and a minimum of ₹1,387.07, reflecting significant growth over the year.
Eris Lifesciences Share Price Target 2026
| When | Maximum Price | Minimum Price |
| January 2026 | 1,857.29 | 1,428.68 |
| February 2026 | 1,810.86 | 1,392.97 |
| March 2026 | 1,847.07 | 1,420.83 |
| April 2026 | 1,884.77 | 1,449.82 |
| May 2026 | 1,866.11 | 1,435.47 |
| June 2026 | 1,912.76 | 1,471.35 |
| July 2026 | 1,875.25 | 1,442.50 |
| August 2026 | 1,933.25 | 1,487.12 |
| September 2026 | 1,971.92 | 1,516.86 |
| October 2026 | 2,023.19 | 1,556.30 |
| November 2026 | 2,073.77 | 1,595.20 |
| December 2026 | 2,125.61 | 1,635.09 |
Eris Lifesciences Share Price Target 2027
| When | Maximum Price | Minimum Price |
| January 2027 | 2,146.87 | 1,651.44 |
| February 2027 | 2,201.91 | 1,693.78 |
| March 2027 | 2,287.79 | 1,759.84 |
| April 2027 | 2,242.93 | 1,725.33 |
| May 2027 | 2,177.60 | 1,675.08 |
| June 2027 | 2,275.59 | 1,750.46 |
| July 2027 | 2,230.98 | 1,716.13 |
| August 2027 | 2,299.97 | 1,769.21 |
| September 2027 | 2,380.47 | 1,831.13 |
| October 2027 | 2,442.37 | 1,878.74 |
| November 2027 | 2,503.43 | 1,925.71 |
| December 2027 | 2,566.01 | 1,973.85 |
Eris Lifesciences Share Price Target 2028
| When | Maximum Price | Minimum Price |
| January 2028 | 2,617.33 | 2,013.33 |
| February 2028 | 2,684.44 | 2,064.96 |
| March 2028 | 2,789.14 | 2,145.49 |
| April 2028 | 2,734.45 | 2,103.42 |
| May 2028 | 2,654.80 | 2,042.16 |
| June 2028 | 2,774.27 | 2,134.05 |
| July 2028 | 2,719.87 | 2,092.21 |
| August 2028 | 2,803.99 | 2,156.92 |
| September 2028 | 2,902.13 | 2,232.41 |
| October 2028 | 2,977.59 | 2,290.45 |
| November 2028 | 3,052.03 | 2,347.71 |
| December 2028 | 3,128.33 | 2,406.40 |
Eris Lifesciences Share Price Target 2029
| When | Maximum Price | Minimum Price |
| January 2029 | 3,190.89 | 2,454.53 |
| February 2029 | 3,272.71 | 2,517.47 |
| March 2029 | 3,400.35 | 2,615.65 |
| April 2029 | 3,333.67 | 2,564.36 |
| May 2029 | 3,236.58 | 2,489.67 |
| June 2029 | 3,382.22 | 2,601.71 |
| July 2029 | 3,315.90 | 2,550.69 |
| August 2029 | 3,418.46 | 2,629.58 |
| September 2029 | 3,538.10 | 2,721.62 |
| October 2029 | 3,630.09 | 2,792.38 |
| November 2029 | 3,720.85 | 2,862.19 |
| December 2029 | 3,813.87 | 2,933.74 |
Eris Lifesciences Share Price Target 2030
| When | Maximum Price | Minimum Price |
| January 2030 | 3,890.14 | 2,992.42 |
| February 2030 | 3,989.89 | 3,069.15 |
| March 2030 | 4,145.50 | 3,188.84 |
| April 2030 | 4,064.21 | 3,126.32 |
| May 2030 | 3,945.84 | 3,035.26 |
| June 2030 | 4,123.40 | 3,171.85 |
| July 2030 | 4,042.55 | 3,109.65 |
| August 2030 | 4,167.58 | 3,205.83 |
| September 2030 | 4,313.44 | 3,318.03 |
| October 2030 | 4,425.59 | 3,404.30 |
| November 2030 | 4,536.23 | 3,489.41 |
| December 2030 | 4,649.64 | 3,576.64 |
In January 2030, Eris Lifesciences is expected to reach a maximum price of ₹3,890.14 and a minimum of ₹2,992.42. By December 2030, the stock is anticipated to peak at ₹4,649.64 with a minimum of ₹3,576.64.
Eris Lifesciences Ltd Financial Condition: Last 5 Years
| Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | TTM | |
| Sales + | 1,074 | 1,212 | 1,347 | 1,685 | 2,009 | 2,262 |
| Expenses + | 702 | 781 | 858 | 1,146 | 1,332 | 1,507 |
| Operating Profit | 372 | 431 | 489 | 539 | 677 | 755 |
| OPM % | 35% | 36% | 36% | 32% | 34% | 33% |
| Other Income + | 12 | 9 | 22 | 9 | 22 | 24 |
| Interest | 2 | 2 | 4 | 26 | 85 | 128 |
| Depreciation | 50 | 43 | 65 | 117 | 183 | 218 |
| Profit before tax | 331 | 394 | 442 | 405 | 431 | 434 |
| Tax % | 11% | 10% | 8% | 8% | 8% | |
| Net Profit + | 297 | 355 | 406 | 374 | 397 | 393 |
| EPS in Rs | 21.84 | 26.16 | 29.88 | 28.1 | 28.82 | 27.95 |
| Dividend Payout % | 13% | 21% | 20% | 26% | 0% |
Eris Lifesciences Ltd has shown strong financial growth from March 2020 to the trailing twelve months (TTM) ending in March 2024, with sales increasing from ₹1,074 crore to ₹2,262 crore, reflecting robust demand. Operating profit rose from ₹372 crore to ₹755 crore, although the Operating Profit Margin (OPM) fluctuated between 32% and 36%. The company experienced a significant rise in expenses, including interest costs, which grew from ₹2 crore to ₹128 crore, and depreciation, which increased from ₹50 crore to ₹218 crore, suggesting higher borrowing and capital investments. Despite these rising costs, net profit increased from ₹297 crore to ₹393 crore, while the earnings per share (EPS) fluctuated, ending at ₹27.95. Dividend payout was inconsistent, peaking at 26% in March 2023 but seeing no payout in March 2024, indicating strategic financial adjustments. Overall, Eris Lifesciences maintained a positive growth trend, balancing revenue expansion with cost management.
FAQs
What Is the Current Stock Price of ERIS Lifesciences?
The current stock price for the company stands at ₹1,448.
What Is the Share Price Target for ERIS Lifesciences By 2025?
The share price target for 2025 shows a range from ₹1,180.83 to ₹1,803.19, reflecting significant fluctuations throughout the year.
What Is the Share Price Target for ERIS Lifesciences By 2030?
The share price target for 2030 exhibits a substantial range, with prices fluctuating between ₹2,992.42 and ₹4,649.64 during the year.
What Is the ERIS Lifesciences Price-to-Earnings ratio?
The company’s Price-to-Earnings (P/E) ratio is 52.2.
Also Read
- Aegis Logistics Ltd Share Price Target 2024, 2025 to 2030
- Jyoti CNC Automation Ltd Share Price Target 2024, 2025 to 2030
- NLC India Ltd Share Price Target 2024, 2025 to 2030
Conclusion
Eris Lifesciences Ltd has demonstrated a robust trajectory in both its financial performance and strategic advancements. The company’s recent acquisition of Biocon Biologics’ India-branded formulations business for ₹1,242 crore marks a significant milestone, bolstering its presence in the insulin market and expanding its portfolio. This move, alongside ChrysCapital’s substantial exit, highlights strong investor confidence and positions Eris for continued growth. Financially, Eris Lifesciences has shown impressive sales growth, increasing from ₹1,074 crore in March 2020 to ₹2,262 crore in the trailing twelve months. Despite rising expenses and interest costs, the company has effectively managed its profitability, with a net profit of ₹393 crore and an EPS of ₹27.95. The anticipated stock price targets for 2025 and 2030 further underscore the company’s potential for substantial appreciation, with significant upward movement projected. Overall, Eris Lifesciences is well-positioned for sustained success, supported by its strategic acquisitions and solid financial fundamentals.
Leave a Reply